GSK 2879552

Key Product Details

Product Description

GSK 2879552 is a selective lysine-specific demethylase 1 (LSD1) inhibitor. When combined with other small molecules (EPZ-5676, N-methyl-d-aspartate and Bay K 8644), GSK 2879552 accelerates maturation of human pluripotent stem cell-derived neurons. GSK 2879552 inhibits the growth of small cell lung carcinoma (SCLC) and AML lines. In vivo, GSK 2879552 (1.5 mg/kg, p.o.) demonstrates tumor growth inhibition in SCLC xenograph mouse models.

Product Specifications for GSK 2879552

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for GSK 2879552

The following data is based on the product molecular weight 437.41.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	4.57 mL	22.86 mL	45.72 mL
2.5 mM	0.91 mL	4.57 mL	9.14 mL
5 mM	0.46 mL	2.29 mL	4.57 mL
25 mM	0.09 mL	0.46 mL	0.91 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Mohammad A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell 2015 PMID: 26175415
• Hergenreder Combined small-molecule treatment accelerates maturation of human pluripotent stem cell-derived neurons. Nat.Biotechnol. 2024 PMID: 38168993

Product Documents for GSK 2879552